PVR and neoplasm: The T-cell immunoglobulin and ITIM domain (TIGIT) is highly expressed on activated T cells and can inhibit T-cell functions after binding to its ligand CD155 on antigen-presenting cells.192 TIGIT, CD96, and CD112R compete as co‐inhibitors for their ligands (CD155 and CD112).193 The inhibition of TIGIT plays a critical role in different stages of tumor development.194 Anti‐TIGIT, anti‐CD96 or anti‐CD112R have all shown anti‐tumor effect in preclinical settings.195–197 However, the immunomodulatory role of CD155 in tumor microenvironment is rarely studied.